No Data
No Data
Medical-B: Shanghai Micro-Invasive Medical and Science Medical reached a distribution framework agreement for Science Medical in 2024.
Medtronic-B (02160) announced that on July 19, 2024 (after the trading session), Shanghai Micromed and Covary Medical signed the 2024 Covary distribution framework agreement. Pursuant to this, Covary Medical agreed to grant Shanghai Micromed the exclusive right to distribute products in China, the term of which shall be from July 19, 2024 to December 31, 2025 (inclusive of the first and last day). On July 19, 2024 (after the trading session), Shanghai Micromed and Covary Medical entered into the Covary loan agreement, pursuant to which Shanghai Micromed (as the lender) agreed to lend to Covary Medical (as the borrower).
Mindray Medical International Limited (02160.HK): Shanghai Microport Mindray Co. signed a 2024 distribution agreement with Koway Medical.
On July 19th, Gelon Hui reported that on July 19, 2024, Shanghai MicroPort CardioFlow and Covidien Medical signed the 2024 Covidien distribution framework agreement. Accordingly, Covidien Medical agreed to grant Shanghai MicroPort CardioFlow the exclusive right to distribute products in China, which will expire from July 19, 2024 to December 31, 2025 (including the first and last day).
China's Medical Device Market Value Hits $179B, 90th CMEF in Shenzhen to Feature a Plethora of Technological Products
The 90th China International Medical Equipment Fair (CMEF) is set to take place in Shenzhen from October 12th to 15th, 2024. With an expected attendance of over 200,000 visitors from more than 150 countries, the exhibition is poised to be a global showcase of cutting-edge technology.
Sinolink Securities: The pharmaceutical sector is expected to see an improvement in market conditions in the third quarter, and overall growth expectations for the second half of the year are optimistic.
Sinolink Securities released a research report stating that considering the improvement in the medical insurance settlement cycle, the expectation of policy improvement, and the recovery performance of the industry, as well as the fact that institutional medicine hold positions are at a low level, the medical sector will usher in an improved market situation in Q3.
MicroPort Scientific Forecasts Decline in Net Loss for H1 on Higher Revenue
MicroPort Scientific (HKG:0853) forecasts a "significant" decline in its net loss for the six months ended June 30 due to a 17% rise in revenue, according to a Monday filing with the Hong Kong Stock
MicroPort CardioFlow Medtech Expects Up to 28% Rise in H1 Revenue
MicroPort CardioFlow Medtech (HKG:2160) forecasts revenue to surge 22% to 28% to between 215 million yuan and 225 million yuan in the first half, according to a Thursday filing with the Hong Kong Stoc
No Data